Emerging therapies for the treatment of skeletal muscle wasting in chronic obstructive pulmonary disease

AuthorsPassey, S.L.
Hansen, M.J.
Bozinovski, S.
McDonald, C.F.
Holland, A.E.
Vlahos, R.
TypeJournal Article (Original Research)
JournalPharmacology & therapeutics
PubMed ID27373503
Year of Publication2016
URLhttp://www.ncbi.nlm.nih.gov/pubmed/27373503
DOIhttp://dx.doi.org/10.1016/j.pharmthera.2016.06.013
Download 1-s20-S0163725816301036-main_.pdf (907.6 KB)
AbstractChronic obstructive pulmonary disease (COPD) is a progressive lung disease that constitutes a major global health burden. A significant proportion of patients experience skeletal muscle wasting and loss of strength as a comorbidity of their COPD, a condition that severely impacts on their quality of life and survival. At present, the lung pathology is considered to be largely irreversible; however, the inherent adaptability of muscle tissue offers therapeutic opportunities to tackle muscle wasting and potentially reverse or delay the progression of this aspect of the disease, to improve patients' quality of life. Muscle wasting in COPD is complex, with contributions from a number of factors including inflammatory cytokines, oxidative stress, growth and anabolic hormones, nutritional status, and physical activity. In this review, we discuss current and emerging therapeutic approaches to treat muscle wasting in COPD, including a number of pharmacological therapies that are in development for muscle atrophy in other pathological states that could be of relevance for treating muscle wasting in COPD patients.

http://www.ibas.org.au/what-we-do/publications/3872823


< More publications



CHEST-MND:PROCHEST-MND:PRO

Motor neurone disease (MND) causes the body's muscles to weaken. Breathing muscle weakness means that most people affected by MND will eventually lose the ability to take a deep breath and cough strongly....

Respiratory Biomarkers in Motor Neurone DiseaseRESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE

The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...

Recognising research meritRECOGNISING RESEARCH MERIT

Kudos to Dr. Lauren Booker & Dr. Jen Cori on their JOEM publication examining fatigue detection alarms in rural truck drivers. Their study explores the alarms' effectiveness, accuracy, and habituation, offering key insights into fatigue management.

Honoring Excellence in ResearchHONORING EXCELLENCE IN RESEARCH

Congratulations to Prof. Anne Holland and A/Prof. Narelle Cox for being featured in the NHMRC's 10 of the Best - 16th Edition. Their work exemplifies groundbreaking research delivering extraordinary outcomes.

World Sleep Day on 14th March 2025WORLD SLEEP DAY ON 14TH MARCH 2025

The benefits of quality sleep and to acknowledge the issue of sleep problems and their medical, educational, and social aspects as well as the prevention and management of sleep disorders, is promoted on World Sleep Day on the 14th March 2025.

AMRF Grant Awards for 2025AMRF GRANT AWARDS FOR 2025

Grants Success: The Institute for Breathing and Sleep (IBAS) has received two research grants from the Austin Medical Research Foundation (AMRF) for 2025. Congratulations to Dr Charissa Zaga and Dr Catherine Hill from IBAS.

Institute for Breathing and Sleep

Level 5, Harold Stokes Building, Austin Health
145 Studley Road
Heidelberg, Victoria, 3084

(03) 9496 5390

Email Us

Donate